SCHEMBL10073860

SCHEMBL10073860

COc1ccc2c(C(=O)c3ccc(C)nc3)n[nH]c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAG1 P54619 3/20 0.44
PRKAA1 Q13131 3/20 0.44
PRKAB1 Q9Y478 3/20 0.44
PRKAB2 O43741 2/20 0.44
PRKAA2 P54646 2/20 0.44
PRKAG3 Q9UGI9 2/20 0.44
PRKAG2 Q9UGJ0 2/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.41
FLT3 P36888 2/20 0.41
DYRK1A Q13627 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
CDK2 P24941 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13794487 0.87 L3MBTL1 (0.47) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL13844083 0.85 DYRK1A (0.43) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL13844093 0.83 PRKAG1 (0.40) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL13844150 0.82 PRKAG1 (0.42) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL13844100 0.82 PRKAG1 (0.39) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL13936217 0.82 PRKAG1 (0.39) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL10073863 0.81 CYP1A2 (0.50) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL13901145 0.81 BCHE (0.40) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL14001681 0.81 TUBB1 (0.52) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL10073867 0.80 SMN1; SMN2 (0.45) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562909-B1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK SHARP & DOHME (US) 2012-06-27 EP disclosed
US-7547720-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-06-16 US disclosed
US-7547720-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-06-16 US disclosed
US-7528163-B2 N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye MERCK & CO. INC. (US) 2009-05-05 US disclosed
US-7528163-B2 N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye MERCK & CO. INC. (US) 2009-05-05 US disclosed
EP-1663987-B1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO INC (US) 2009-03-18 EP disclosed
US-7494983-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-02-24 US disclosed
US-7494983-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-02-24 US disclosed
US-7410992-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2008-08-12 US disclosed
US-7410992-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2008-08-12 US disclosed
US-20070129418-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME LLC 2007-06-07 US disclosed
US-20070129418-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME LLC 2007-06-07 US disclosed
US-7196082-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2007-03-27 US disclosed
US-7196082-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2007-03-27 US disclosed
US-20070027188-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2007-02-01 US disclosed
US-20070027188-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2007-02-01 US disclosed
US-20070010491-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME LLC 2007-01-11 US disclosed
US-20070010491-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME LLC 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010491-A1 Ophthalmic compositions for treating ocular hypertension REN, KCNH2, KCNH3 PRKAG1 2052/4885PRKAA1 1487/4885PRKAB1 1338/4885
US-20070027188-A1 Ophthalmic compositions for treating ocular hypertension KCNH2, KCNN1, KCNH3 PRKAG1 1021/4885PRKAA1 1832/4885PRKAB1 701/4885
US-20070129418-A1 Ophthalmic compositions for treating ocular hypertension KCNH2, KCNJ11, KCNN1 PRKAG1 966/4885PRKAA1 2015/4885PRKAB1 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.